Actively Recruiting
68Ga-P3 PET/CT Imaging in Malignancy
Led by Peking University First Hospital · Updated on 2024-11-07
350
Participants Needed
1
Research Sites
114 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies. \[68Ga\]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA high-expression malignanciesr.
CONDITIONS
Official Title
68Ga-P3 PET/CT Imaging in Malignancy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with confirmed or suspected cancer
- Age between 18 and 75 years
- 18F-FDG PET/CT scan performed within 1 week prior to enrollment
- Signed written informed consent
You will not qualify if you...
- Pregnant or breastfeeding women
- Female patients planning to become pregnant within 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
Actively Recruiting
Research Team
X
Xing Yang, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here